An Overview of the Epidemiology, Pathogenesis, Diagnosis, and Treatment of Human Parvovirus B19
Asian Journal of Research in Infectious Diseases,
Page 32-43
DOI:
10.9734/ajrid/2022/v11i4226
Abstract
Human Parvovirus B19 (HPV-B19) infections are reported from different parts of the globe. The infection occurs in all age groups; however, most infections occur in childhood. There is evidence of exposure to the virus in about 80% of adults when screened for specific IgG. HPV-B19 is incriminated in several conditions like erythema infectious, aplastic crisis, hydrops fetalis and arthropathy. HPV-B19 is a cause of the Fifth disease (erythema infectious); it could also cause a febrile illness with or without rash in adults. Many adults especially women develop arthropathy and the condition could be chronic following a febrile illness. Patients (adults) with End Stage Renal Disease (ESRD) are prone to develop aplastic crisis or chronic anemia [1]. This review article aims to comprehensively describe the etiology, epidemiology, clinical features, diagnostic methods, and treatment in the management of HPV-B19.
Keywords:
- Arthropathy
- End-stage renal disease
- febrile illness
- IgM
- HPV-B19
How to Cite
Vadivel, K., Nandagopal, B., Ramamurthy, M., Saravanan, N., & Rajendiran, P. (2022). An Overview of the Epidemiology, Pathogenesis, Diagnosis, and Treatment of Human Parvovirus B19. Asian Journal of Research in Infectious Diseases, 11(4), 32-43. https://doi.org/10.9734/ajrid/2022/v11i4226
References
Ozeki M, Fukushima T, Ohzeki M, Sasaki T, Kashihara N. A nosocomial parvovirus B19 infection-induced transient aplastic crisis in a patient with chronic renal failure. Clin Nephrol. 2006;65(2):141-3.
PMID: 16509466.
DOI: 10.5414/cnp65141
Pedranti MS, Barbero P, Wolff C, Ghietto LM, Zapata M, Adamo MP. Infection and immunity for human parvovirus B19 in patients with febrile exanthema. Epidemiol Infect. 2012;140(3):454-61. Epub 2011 May 18. PMID: 21676356.
DOI: 10.1017/S0950268811000823
Kerr JR. Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis. 2000;59(9):672-83. PMID: 10976079; PMCID: PMC1753262.
DOI: 10.1136/ard.59.9.672
Kerr JR, Tyrrell DA. Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome. Curr Pain Headache Rep. 2003;7(5):333-41. PMID: 12946285.
DOI: 10.1007/s11916-003-0031-3
Zádori Z, Szelei J, Lacoste MC, Li Y, Gariépy S, Raymond P, et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell. 2001; 1(2):291-302. PMID: 11702787.
DOI: 10.1016/s1534-5807(01)00031-4
Parsyan A, Szmaragd C, Allain JP, Candotti D. Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J Gen Virol. 2007;88(Pt 2):428-431.
PMID: 17251559.
DOI: 10.1099/vir.0.82496-0
Toan NL, Duechting A, Kremsner PG, Song LH, Ebinger M, Aberle S, et al. Phylogenetic analysis of human parvovirus B19, indicating two subgroups of genotype 1 in Vietnamese patients. J Gen Virol. 2006;87(Pt 10):2941-2949.
PMID: 16963753
DOI: 10.1099/vir.0.82037-0
Dorsch S, Liebisch G, Kaufmann B, von Landenberg P, Hoffmann JH, Drobnik W, et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol. 2002;76(4):2014-8. PMID: 11799199; PMCID: PMC135890
DOI: 10.1128/jvi.76.4.2014-2018.2002
Tolfvenstam T, Rudén U, Broliden K. Evaluation of serological assays for identification of parvovirus B19 immunoglobulin M. Clin Diagn Lab Immunol. 1996;3(2):147-50. PMID: 8991627; PMCID: PMC170264.
DOI: 10.1128/cdli.3.2.147-150.1996
Corcoran A, Doyle S, Allain JP, Candotti D, Parsyan A. Evidence of serological cross-reactivity between genotype 1 and genotype 3 erythrovirus infections. J Virol. 2005;79(8):5238-9. PMID: 15795309; PMCID: PMC1069586.
DOI: 10.1128/JVI.79.8.5238-5239.2005
Srivastava A, Lu L. Replication of B19 parvovirus in highly enriched hematopoietic progenitor cells from normal human bone marrow. J Virol. 1988;62(8):3059-63. PMID: 3392774; PMCID: PMC253750.
DOI: 10.1128/JVI.62.8.3059-3063.1988
Kelly HA, Siebert D, Hammond R, Leydon J, Kiely P, Maskill W. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect. 2000;124(3):449-57. PMID: 10982069; PMCID: PMC2810931.
DOI: 10.1017/s0950268899003817
Serjeant GR, Serjeant BE, Thomas PW, Anderson MJ, Patou G, Pattison JR. Human parvovirus infection in homozygous sickle cell disease. Lancet. 1993;341(8855):1237-40. PMID: 8098391
DOI: 10.1016/0140-6736(93)91145-c
Harrison J, Jones CE. Human parvovirus B19 infection in healthcare workers. Occup Med (Lond). 1995;45(2):93-6. PMID: 7718826.
DOI: 10.1093/occmed/45.2.93
Gillespie SM, Cartter ML, Asch S, Rokos JB, Gary GW, Tsou CJ, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA. 1990;263(15):2061-5. PMID: 2157074.
Bell LM, Naides SJ, Stoffman P, Hodinka RL, Plotkin SA. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med. 1989; 321(8):485-91. PMID: 2548096.
DOI: 10.1056/NEJM198908243210801
Dowell SF, Török TJ, Thorp JA, Hedrick J, Erdman DD, Zaki SR, et al. Parvovirus B19 infection in hospital workers: Community or hospital acquisition? J Infect Dis. 1995;172(4):1076-9.
PMID: 7561182.
DOI: 10.1093/infdis/172.4.1076
Ray SM, Erdman DD, Berschling JD, Cooper JE, Török TJ, Blumberg HM. Nosocomial exposure to parvovirus B19: Low risk of transmission to healthcare workers. Infect Control Hosp Epidemiol. 1997;18(2):109-14. PMID: 9120238
DOI: 10.1086/647564
Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev. 1999;13(3):194-204. PMID: 10425692.
DOI: 10.1016/s0887-7963(99)80033-9
Seng C, Watkins P, Morse D, Barrett SP, Zambon M, Andrews N, et al. Parvovirus B19 outbreak on an adult ward. Epidemiol Infect. 1994;113(2):345-53.
PMID: 7925671; PMCID: PMC2271527.
DOI: 10.1017/s0950268800051773
Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: Prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang. 1998;75(2):97-102. PMID: 9784661.
Yu MY, Alter HJ, Virata-Theimer ML, Geng Y, Ma L, Schechterly CA, at al. Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion. 2010;50(8):1712-21. Epub 2010 Feb 12. PMID: 20158689; PMCID: PMC5547753.
DOI: 10.1111/j.1537-2995.2010.02591.x
Cartter ML, Farley TA, Rosengren S, Quinn DL, Gillespie SM, Gary GW, et al. Occupational risk factors for infection with parvovirus B19 among pregnant women. J Infect Dis. 1991;163(2):282-5. PMID: 1846391.
DOI: 10.1093/infdis/163.2.282
Jordan JA. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol. 1996;174(1 Pt 1):37-42. PMID: 8572031
DOI: 10.1016/s0002-9378(96)70370-8
Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med. 2006;260(4):285-304. PMID: 16961667.
DOI: 10.1111/j.1365-2796.2006.01697.x
Flunker G, Peters A, Wiersbitzky S, Modrow S, Seidel W. Persistent parvovirus B19 infections in immunocompromised children. Med Microbiol Immunol. 1998;186(4):189-94. PMID: 9574901.
DOI: 10.1007/s004300050063
Röhrer C, Gärtner B, Sauerbrei A, Böhm S, Hottenträger B, Raab U, et al. Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect. 2008;136(11):1564-75. Epub 2008 Jan 16. PMID: 18198003; PMCID: PMC2870752
DOI: 10.1017/S0950268807009958
Jain P, Jain A, Prakash S, Khan DN, Singh DD, Kumar A, et al. Prevalence and genotypic characterization of human parvovirus B19 in children with hemato-oncological disorders in North India. J Med Virol. 2015;87(2):303-9. Epub 2014 Aug 2. PMID: 25087946.
DOI: 10.1002/jmv.24028
Juhl D, Steppat D, Görg S, Hennig H. Parvovirus b19 infections and blood counts in blood donors. Transfus Med Hemother. 2014;41(1):52-9. Epub 2013 Dec 30. PMID: 24659948; PMCID: PMC3949617.
DOI: 10.1159/000357650
Wildig J, Mueller I, Kiniboro B, Maraga S, Siba P, Cossart Y. Seroprevalence of antibodies to parvovirus B19 among children in Papua New Guinea. Am J Trop Med Hyg. 2007;77(2):354-7. PMID: 17690412
Mor O, Ofir I, Pavel R, Bassal R, Kra-Oz Z, Cohen D, et al. Parvovirus B19V infection in Israel: prevalence and occurrence of acute infection between 2008 and 2013. Epidemiol Infect. 2016;144(1):207-14.
Epub 2015 May 20. PMID: 25990962; PMCID: PMC9507271.
DOI: 10.1017/S0950268815000230
Adam O, Makkawi T, Reber U, Kirberg H, Eis-Hübinger AM. The seroprevalence of parvovirus B19 infection in pregnant women in Sudan. Epidemiol Infect. 2015;143(2):242-8. Epub 2014 Mar 20. PMID: 24650427; PMCID: PMC9206789.
DOI: 10.1017/S0950268814000600
Ke L, He M, Li C, Liu Y, Gao L, Yao F, et al. The prevalence of human parvovirus B19 DNA and antibodies in blood donors from four Chinese blood centers. Transfusion. 2011;51(9):1909-18. Epub 2011 Mar 7. PMID: 21382040.
DOI: 10.1111/j.1537-2995.2011.03067.x
de Freitas RB, Wong D, Boswell F, de Miranda MF, Linhares AC, Shirley J, et al. Prevalence of human parvovirus (B19) and rubella virus infections in urban and remote rural areas in northern Brazil. J Med Virol. 1990;32(4):203-8. PMID: 1964474
DOI: 10.1002/jmv.1890320402
Jain P, Jain A, Prakash S, Khan DN, Singh DD, Kumar A, et al. Prevalence and genotypic characterization of human parvovirus B19 in children with hemato-oncological disorders in North India. J Med Virol. 2015;87(2):303-9. Epub 2014 Aug 2. PMID: 25087946.
DOI: 10.1002/jmv.24028
Juhl D, Steppat D, Görg S, Hennig H. Parvovirus b19 infections and blood counts in blood donors. Transfus Med Hemother. 2014;41(1):52-9. Epub 2013 Dec 30. PMID: 24659948; PMCID: PMC3949617
DOI: 10.1159/000357650
Ros C, Gerber M, Kempf C. Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol. 2006;80(24):12017-24. Epub 2006 Oct 4. PMID: 17020940; PMCID: PMC1676260.
DOI: 10.1128/JVI.01435-06
Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med. 1989;149(5):1153-6. PMID: 2541666
Chorba T, Coccia P, Holman RC, Tattersall P, Anderson LJ, Sudman J, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis. 1986;154(3):383-93. PMID: 3016109.
DOI: 10.1093/infdis/154.3.383
Wildig J, Michon P, Siba P, Mellombo M, Ura A, Mueller I, et al. Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis. 2006;194(2):146-53. Epub 2006 Jun 14. PMID: 16779719.
DOI: 10.1086/505082
Lefrère JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, et al. Persistent B19 infection in immuno-competent individuals: Implications for transfusion safety. Blood. 2005;106(8):2890-5. Epub 2005 Jun 23. PMID: 15976179.
DOI: 10.1182/blood-2005-03-1053
Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350(6):586-97. PMID: 14762186. DOI: 10.1056/NEJMra030840
Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, et al. Experimental parvoviral infection in humans. J Infect Dis. 1985; 152(2):257-65. PMID: 2993431.
DOI: 10.1093/infdis/152.2.257
Lindblom A, Isa A, Norbeck O, Wolf S, Johansson B, Broliden K, et al. Slow clearance of human parvovirus B19 viremia following acute infection. Clin Infect Dis. 2005;41(8):1201-3. Epub 2005 Sep 2. PMID: 16163641.
DOI: 10.1086/444503
Lowry SM, Brent LH, Menaldino S, Kerr JR. A case of persistent parvovirus B19 infection with bilateral cartilaginous and ligamentous damage to the wrists. Clin Infect Dis. 2005;41(4):e42-4. Epub 2005 Jul 14. PMID: 16028146
DOI: 10.1086/432118
White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA. Human parvovirus arthropathy. Lancet. 1985;1(8426):419-21. PMID: 2857804.
DOI: 10.1016/s0140-6736(85)91145-6
Serjeant BE, Hambleton IR, Kerr S, Kilty CG, Serjeant GR. Haematological response to parvovirus B19 infection in homozygous sickle-cell disease. Lancet. 2001;358(9295):1779-80.
PMID: 11734237.
DOI: 10.1016/S0140-6736(01)06807-6
Young NS. Hematologic manifestations and diagnosis of parvovirus B19 infections. Clin Adv Hematol Oncol. 2006;4(12):908-10. PMID: 17235275.
Musiani M, Pasini P, Zerbini M, Gentilomi G, Roda A, Gallinella G, et al. Prenatal diagnosis of parvovirus B19-induced hydrops fetalis by chemiluminescence in situ hybridization. J Clin Microbiol. 1999;37(7):2326-9. PMID: 10364606; PMCID: PMC85149.
DOI: 10.1128/JCM.37.7.2326-2329.1999
Ramirez MM, Mastrobattista JM. Diagnosis and management of human parvovirus B19 infection. Clin Perinatol. 2005 Sep; 32(3):697-704. PMID: 16085027.
DOI: 10.1016/j.clp.2005.04.003
Grabarczyk P, Kalińska A, Kara M, Wieczorek R, Ejduk A, Sulkowska E, et al. Identification and characterization of acute infection with parvovirus B19 genotype 2 in immuno-compromised patients in Poland. J Med Virol. 2011;83(1):142-9. PMID: 21108352.
DOI: 10.1002/jmv.21947
Jordan JA. Diagnosing human parvovirus B19 infection: Guidelines for test selection. Mol Diagn. 2001;6(4):307-12. PMID: 11774195.
DOI: 10.1054/modi.2001.28632
Manaresi E, Gallinella G, Zuffi E, Bonvicini F, Zerbini M, Musiani M. Diagnosis and quantitative evaluation of parvovirus B19 infections by real-time PCR in the clinical laboratory. J Med Virol. 2002;67(2):275-81. PMID: 11992590.
DOI: 10.1002/jmv.2218
Poole BD, Karetnyi YV, Naides SJ. Parvovirus B19-induced apoptosis of hepatocytes. J Virol. 2004;78(14):7775- 83. PMID: 15220451; PMCID: PMC434113.
DOI: 10.1128/JVI.78.14.7775-7783.2004
Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med. 1989;321(8):519-23. PMID: 2548098
DOI: 10.1056/NEJM198908243210807
Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O, et al; Groupe d'experts de l'Assistance Publique-Hôpitaux de Paris. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56(7):968-77. Epub 2012 Dec 12. PMID: 23243178.
DOI: 10.1093/cid/cis1046
Garewal G, Ahluwalia J, Das R, Marwaha RK. Parvovirus B19-associated transient red cell aplasia in children: The role of bone marrow examination in unusual presentations. Pediatr Hematol Oncol. 2004;21(6):505-11.
PMID: 15552814.
DOI: 10.1080/08880010490477293
Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med. 2006;260(4):285-304. PMID: 16961667.
DOI: 10.1111/j.1365-2796.2006.01697.x
Bonvicini F, Bua G, Manaresi E, Gallinella G. Antiviral effect of cidofovir on parvovirus B19 replication. Antiviral Res. 2015; 113:11-8. Epub 2014 Nov 13. PMID: 25446336.
DOI: 10.1016/j.antiviral.2014.11.004
PMID: 16509466.
DOI: 10.5414/cnp65141
Pedranti MS, Barbero P, Wolff C, Ghietto LM, Zapata M, Adamo MP. Infection and immunity for human parvovirus B19 in patients with febrile exanthema. Epidemiol Infect. 2012;140(3):454-61. Epub 2011 May 18. PMID: 21676356.
DOI: 10.1017/S0950268811000823
Kerr JR. Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis. 2000;59(9):672-83. PMID: 10976079; PMCID: PMC1753262.
DOI: 10.1136/ard.59.9.672
Kerr JR, Tyrrell DA. Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome. Curr Pain Headache Rep. 2003;7(5):333-41. PMID: 12946285.
DOI: 10.1007/s11916-003-0031-3
Zádori Z, Szelei J, Lacoste MC, Li Y, Gariépy S, Raymond P, et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell. 2001; 1(2):291-302. PMID: 11702787.
DOI: 10.1016/s1534-5807(01)00031-4
Parsyan A, Szmaragd C, Allain JP, Candotti D. Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J Gen Virol. 2007;88(Pt 2):428-431.
PMID: 17251559.
DOI: 10.1099/vir.0.82496-0
Toan NL, Duechting A, Kremsner PG, Song LH, Ebinger M, Aberle S, et al. Phylogenetic analysis of human parvovirus B19, indicating two subgroups of genotype 1 in Vietnamese patients. J Gen Virol. 2006;87(Pt 10):2941-2949.
PMID: 16963753
DOI: 10.1099/vir.0.82037-0
Dorsch S, Liebisch G, Kaufmann B, von Landenberg P, Hoffmann JH, Drobnik W, et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol. 2002;76(4):2014-8. PMID: 11799199; PMCID: PMC135890
DOI: 10.1128/jvi.76.4.2014-2018.2002
Tolfvenstam T, Rudén U, Broliden K. Evaluation of serological assays for identification of parvovirus B19 immunoglobulin M. Clin Diagn Lab Immunol. 1996;3(2):147-50. PMID: 8991627; PMCID: PMC170264.
DOI: 10.1128/cdli.3.2.147-150.1996
Corcoran A, Doyle S, Allain JP, Candotti D, Parsyan A. Evidence of serological cross-reactivity between genotype 1 and genotype 3 erythrovirus infections. J Virol. 2005;79(8):5238-9. PMID: 15795309; PMCID: PMC1069586.
DOI: 10.1128/JVI.79.8.5238-5239.2005
Srivastava A, Lu L. Replication of B19 parvovirus in highly enriched hematopoietic progenitor cells from normal human bone marrow. J Virol. 1988;62(8):3059-63. PMID: 3392774; PMCID: PMC253750.
DOI: 10.1128/JVI.62.8.3059-3063.1988
Kelly HA, Siebert D, Hammond R, Leydon J, Kiely P, Maskill W. The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect. 2000;124(3):449-57. PMID: 10982069; PMCID: PMC2810931.
DOI: 10.1017/s0950268899003817
Serjeant GR, Serjeant BE, Thomas PW, Anderson MJ, Patou G, Pattison JR. Human parvovirus infection in homozygous sickle cell disease. Lancet. 1993;341(8855):1237-40. PMID: 8098391
DOI: 10.1016/0140-6736(93)91145-c
Harrison J, Jones CE. Human parvovirus B19 infection in healthcare workers. Occup Med (Lond). 1995;45(2):93-6. PMID: 7718826.
DOI: 10.1093/occmed/45.2.93
Gillespie SM, Cartter ML, Asch S, Rokos JB, Gary GW, Tsou CJ, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA. 1990;263(15):2061-5. PMID: 2157074.
Bell LM, Naides SJ, Stoffman P, Hodinka RL, Plotkin SA. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med. 1989; 321(8):485-91. PMID: 2548096.
DOI: 10.1056/NEJM198908243210801
Dowell SF, Török TJ, Thorp JA, Hedrick J, Erdman DD, Zaki SR, et al. Parvovirus B19 infection in hospital workers: Community or hospital acquisition? J Infect Dis. 1995;172(4):1076-9.
PMID: 7561182.
DOI: 10.1093/infdis/172.4.1076
Ray SM, Erdman DD, Berschling JD, Cooper JE, Török TJ, Blumberg HM. Nosocomial exposure to parvovirus B19: Low risk of transmission to healthcare workers. Infect Control Hosp Epidemiol. 1997;18(2):109-14. PMID: 9120238
DOI: 10.1086/647564
Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev. 1999;13(3):194-204. PMID: 10425692.
DOI: 10.1016/s0887-7963(99)80033-9
Seng C, Watkins P, Morse D, Barrett SP, Zambon M, Andrews N, et al. Parvovirus B19 outbreak on an adult ward. Epidemiol Infect. 1994;113(2):345-53.
PMID: 7925671; PMCID: PMC2271527.
DOI: 10.1017/s0950268800051773
Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: Prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang. 1998;75(2):97-102. PMID: 9784661.
Yu MY, Alter HJ, Virata-Theimer ML, Geng Y, Ma L, Schechterly CA, at al. Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples. Transfusion. 2010;50(8):1712-21. Epub 2010 Feb 12. PMID: 20158689; PMCID: PMC5547753.
DOI: 10.1111/j.1537-2995.2010.02591.x
Cartter ML, Farley TA, Rosengren S, Quinn DL, Gillespie SM, Gary GW, et al. Occupational risk factors for infection with parvovirus B19 among pregnant women. J Infect Dis. 1991;163(2):282-5. PMID: 1846391.
DOI: 10.1093/infdis/163.2.282
Jordan JA. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol. 1996;174(1 Pt 1):37-42. PMID: 8572031
DOI: 10.1016/s0002-9378(96)70370-8
Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med. 2006;260(4):285-304. PMID: 16961667.
DOI: 10.1111/j.1365-2796.2006.01697.x
Flunker G, Peters A, Wiersbitzky S, Modrow S, Seidel W. Persistent parvovirus B19 infections in immunocompromised children. Med Microbiol Immunol. 1998;186(4):189-94. PMID: 9574901.
DOI: 10.1007/s004300050063
Röhrer C, Gärtner B, Sauerbrei A, Böhm S, Hottenträger B, Raab U, et al. Seroprevalence of parvovirus B19 in the German population. Epidemiol Infect. 2008;136(11):1564-75. Epub 2008 Jan 16. PMID: 18198003; PMCID: PMC2870752
DOI: 10.1017/S0950268807009958
Jain P, Jain A, Prakash S, Khan DN, Singh DD, Kumar A, et al. Prevalence and genotypic characterization of human parvovirus B19 in children with hemato-oncological disorders in North India. J Med Virol. 2015;87(2):303-9. Epub 2014 Aug 2. PMID: 25087946.
DOI: 10.1002/jmv.24028
Juhl D, Steppat D, Görg S, Hennig H. Parvovirus b19 infections and blood counts in blood donors. Transfus Med Hemother. 2014;41(1):52-9. Epub 2013 Dec 30. PMID: 24659948; PMCID: PMC3949617.
DOI: 10.1159/000357650
Wildig J, Mueller I, Kiniboro B, Maraga S, Siba P, Cossart Y. Seroprevalence of antibodies to parvovirus B19 among children in Papua New Guinea. Am J Trop Med Hyg. 2007;77(2):354-7. PMID: 17690412
Mor O, Ofir I, Pavel R, Bassal R, Kra-Oz Z, Cohen D, et al. Parvovirus B19V infection in Israel: prevalence and occurrence of acute infection between 2008 and 2013. Epidemiol Infect. 2016;144(1):207-14.
Epub 2015 May 20. PMID: 25990962; PMCID: PMC9507271.
DOI: 10.1017/S0950268815000230
Adam O, Makkawi T, Reber U, Kirberg H, Eis-Hübinger AM. The seroprevalence of parvovirus B19 infection in pregnant women in Sudan. Epidemiol Infect. 2015;143(2):242-8. Epub 2014 Mar 20. PMID: 24650427; PMCID: PMC9206789.
DOI: 10.1017/S0950268814000600
Ke L, He M, Li C, Liu Y, Gao L, Yao F, et al. The prevalence of human parvovirus B19 DNA and antibodies in blood donors from four Chinese blood centers. Transfusion. 2011;51(9):1909-18. Epub 2011 Mar 7. PMID: 21382040.
DOI: 10.1111/j.1537-2995.2011.03067.x
de Freitas RB, Wong D, Boswell F, de Miranda MF, Linhares AC, Shirley J, et al. Prevalence of human parvovirus (B19) and rubella virus infections in urban and remote rural areas in northern Brazil. J Med Virol. 1990;32(4):203-8. PMID: 1964474
DOI: 10.1002/jmv.1890320402
Jain P, Jain A, Prakash S, Khan DN, Singh DD, Kumar A, et al. Prevalence and genotypic characterization of human parvovirus B19 in children with hemato-oncological disorders in North India. J Med Virol. 2015;87(2):303-9. Epub 2014 Aug 2. PMID: 25087946.
DOI: 10.1002/jmv.24028
Juhl D, Steppat D, Görg S, Hennig H. Parvovirus b19 infections and blood counts in blood donors. Transfus Med Hemother. 2014;41(1):52-9. Epub 2013 Dec 30. PMID: 24659948; PMCID: PMC3949617
DOI: 10.1159/000357650
Ros C, Gerber M, Kempf C. Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol. 2006;80(24):12017-24. Epub 2006 Oct 4. PMID: 17020940; PMCID: PMC1676260.
DOI: 10.1128/JVI.01435-06
Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med. 1989;149(5):1153-6. PMID: 2541666
Chorba T, Coccia P, Holman RC, Tattersall P, Anderson LJ, Sudman J, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis. 1986;154(3):383-93. PMID: 3016109.
DOI: 10.1093/infdis/154.3.383
Wildig J, Michon P, Siba P, Mellombo M, Ura A, Mueller I, et al. Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis. 2006;194(2):146-53. Epub 2006 Jun 14. PMID: 16779719.
DOI: 10.1086/505082
Lefrère JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, et al. Persistent B19 infection in immuno-competent individuals: Implications for transfusion safety. Blood. 2005;106(8):2890-5. Epub 2005 Jun 23. PMID: 15976179.
DOI: 10.1182/blood-2005-03-1053
Young NS, Brown KE. Parvovirus B19. N Engl J Med. 2004;350(6):586-97. PMID: 14762186. DOI: 10.1056/NEJMra030840
Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, et al. Experimental parvoviral infection in humans. J Infect Dis. 1985; 152(2):257-65. PMID: 2993431.
DOI: 10.1093/infdis/152.2.257
Lindblom A, Isa A, Norbeck O, Wolf S, Johansson B, Broliden K, et al. Slow clearance of human parvovirus B19 viremia following acute infection. Clin Infect Dis. 2005;41(8):1201-3. Epub 2005 Sep 2. PMID: 16163641.
DOI: 10.1086/444503
Lowry SM, Brent LH, Menaldino S, Kerr JR. A case of persistent parvovirus B19 infection with bilateral cartilaginous and ligamentous damage to the wrists. Clin Infect Dis. 2005;41(4):e42-4. Epub 2005 Jul 14. PMID: 16028146
DOI: 10.1086/432118
White DG, Woolf AD, Mortimer PP, Cohen BJ, Blake DR, Bacon PA. Human parvovirus arthropathy. Lancet. 1985;1(8426):419-21. PMID: 2857804.
DOI: 10.1016/s0140-6736(85)91145-6
Serjeant BE, Hambleton IR, Kerr S, Kilty CG, Serjeant GR. Haematological response to parvovirus B19 infection in homozygous sickle-cell disease. Lancet. 2001;358(9295):1779-80.
PMID: 11734237.
DOI: 10.1016/S0140-6736(01)06807-6
Young NS. Hematologic manifestations and diagnosis of parvovirus B19 infections. Clin Adv Hematol Oncol. 2006;4(12):908-10. PMID: 17235275.
Musiani M, Pasini P, Zerbini M, Gentilomi G, Roda A, Gallinella G, et al. Prenatal diagnosis of parvovirus B19-induced hydrops fetalis by chemiluminescence in situ hybridization. J Clin Microbiol. 1999;37(7):2326-9. PMID: 10364606; PMCID: PMC85149.
DOI: 10.1128/JCM.37.7.2326-2329.1999
Ramirez MM, Mastrobattista JM. Diagnosis and management of human parvovirus B19 infection. Clin Perinatol. 2005 Sep; 32(3):697-704. PMID: 16085027.
DOI: 10.1016/j.clp.2005.04.003
Grabarczyk P, Kalińska A, Kara M, Wieczorek R, Ejduk A, Sulkowska E, et al. Identification and characterization of acute infection with parvovirus B19 genotype 2 in immuno-compromised patients in Poland. J Med Virol. 2011;83(1):142-9. PMID: 21108352.
DOI: 10.1002/jmv.21947
Jordan JA. Diagnosing human parvovirus B19 infection: Guidelines for test selection. Mol Diagn. 2001;6(4):307-12. PMID: 11774195.
DOI: 10.1054/modi.2001.28632
Manaresi E, Gallinella G, Zuffi E, Bonvicini F, Zerbini M, Musiani M. Diagnosis and quantitative evaluation of parvovirus B19 infections by real-time PCR in the clinical laboratory. J Med Virol. 2002;67(2):275-81. PMID: 11992590.
DOI: 10.1002/jmv.2218
Poole BD, Karetnyi YV, Naides SJ. Parvovirus B19-induced apoptosis of hepatocytes. J Virol. 2004;78(14):7775- 83. PMID: 15220451; PMCID: PMC434113.
DOI: 10.1128/JVI.78.14.7775-7783.2004
Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med. 1989;321(8):519-23. PMID: 2548098
DOI: 10.1056/NEJM198908243210807
Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O, et al; Groupe d'experts de l'Assistance Publique-Hôpitaux de Paris. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56(7):968-77. Epub 2012 Dec 12. PMID: 23243178.
DOI: 10.1093/cid/cis1046
Garewal G, Ahluwalia J, Das R, Marwaha RK. Parvovirus B19-associated transient red cell aplasia in children: The role of bone marrow examination in unusual presentations. Pediatr Hematol Oncol. 2004;21(6):505-11.
PMID: 15552814.
DOI: 10.1080/08880010490477293
Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med. 2006;260(4):285-304. PMID: 16961667.
DOI: 10.1111/j.1365-2796.2006.01697.x
Bonvicini F, Bua G, Manaresi E, Gallinella G. Antiviral effect of cidofovir on parvovirus B19 replication. Antiviral Res. 2015; 113:11-8. Epub 2014 Nov 13. PMID: 25446336.
DOI: 10.1016/j.antiviral.2014.11.004
-
Abstract View: 126 times
PDF Download: 53 times
